Research Study

Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma
Principal Investigator 
Sasha Smiljanic

Overview

Body Locations and Systems 
Melanoma
Disorders and Conditions 
Melanoma
ClinicalTrials.gov# 
NCT02186249
Status 
Closed to Recruitment
Study Start/End 
Apr 15, 2016 to Jul 1, 2020
Locations 
North Shore Community (including Horseshoe Bay and up to Lions Bay)
Name/Title 
Valla Sahraei, Research Coordinator
Phone 
604-988-3131 ext.4934
Email Address 
valla.sahraei@vch.ca
Purpose of Study 

The purpose of this study is to provide treatment with nivolumab in combination with ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma.
 

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.